Tag: factor xii inhibitors market growth

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Factor XII Inhibitors Market Forecast: What Value Will The Market Reach By 2030?

The factor xii inhibitors market has expanded considerably in recent years. It is anticipated to increase from $1.4 billion in 2025 to $1.55 billion in 2026, registering a compound annual growth rate (CAGR) of 11.1%. The expansion observed historically can be attributed to progress in coagulation biology research, a rise in the occurrence of thrombotic disorders, deficiencies of conventional anticoagulants, early positive outcomes in fxii inhibition clinical trials, and increased investment in niche and specialized treatments.

The market size for factor xii inhibitors is anticipated to grow significantly in the coming years. This market is forecast to reach a valuation of $2.34 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 10.8%. Key drivers for this growth during the projection period include the broader scope of late-stage clinical trials, a surging need for safer antithrombotic treatments, the increasing integration of precision medicine, enhanced regulatory backing for new anticoagulants, and the application of fxii inhibitors in inflammatory conditions. Significant trends observed within this period encompass the escalating creation of non-bleeding anticoagulant solutions, a heightened emphasis on modulating targeted coagulation pathways, expanding clinical assessments of fxii selective inhibitors, the broader adoption of rna-based and peptide therapeutic approaches, and improved utilization of precision drug design.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=21456993&type=smp&name=Factor%20XII%20Inhibitors%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Factor XII Inhibitors Market Industry Drivers: What’s Behind The Revenue Growth?

The increasing occurrence of thrombotic conditions is anticipated to fuel the expansion of the factor XII inhibitors market. Thromboembolic conditions involve the development of blood clots within veins or arteries, which can obstruct blood flow and lead to severe health issues. The prevalence of these disorders is growing due to the rise in inactive lifestyles, which contribute to inadequate blood circulation and an elevated chance of clot formation. In managing thrombotic disorders, Factor XII inhibitors assist in preventing pathological clot formation by obstructing the contact activation pathway without disturbing normal blood clotting. This facilitates effective management of thrombosis with a reduced chance of hemorrhage. For instance, in January 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, approximately 900,000 people in the United States are affected by venous thromboembolism, of which an estimated 60,000-100,000 Americans die annually, while many others experience long-term complications. Consequently, the escalating incidence of thrombotic disorders is boosting the growth of the Factor XII inhibitors market.

Factor XII Inhibitors Market Breakdown By Product Type And Application

The factor xii inhibitors market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Application: Hereditary Angioedema, Thrombosis, Inflammatory Disorders, Other Applications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors

3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies

#Factor XII Inhibitors Market Growth Trends: What’s Shaping The Future Outlook?

Leading companies in the Factor XII Inhibitors market are concentrating on developing innovative products, such as anti-FXIIa monoclonal antibodies, to enhance therapeutic precision and treatment effectiveness. These anti-FXIIa monoclonal antibodies are targeted biologics designed to inhibit activated factor XII, preventing abnormal clot formation while preserving normal hemostasis. For instance, in February 2025, CSL Behring GmbH, a Germany-based biopharmaceutical company, received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This product is a novel, human anti-activated factor XII monoclonal antibody approved for the prevention of acute attacks of hereditary angioedema (HAE). It functions by targeting activated factor XIIa, a key driver in the initiation of HAE attacks, and is administered through a convenient subcutaneous injection pen.

Factor XII Inhibitors Market Company Landscape And Competitive Strategy

Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC

View The Full Factor XII Inhibitors Market Report:

https://thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Factor XII Inhibitors Market Regional Outlook: Where Is Opportunity Concentrated?

North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Factor XII Inhibitors Market Size And Revenue Forecast Through 2030

In recent years, the market for factor XII inhibitors has expanded rapidly, rising from $1.4 billion in 2025 to an anticipated $1.55 billion in 2026, representing a compound annual growth rate (CAGR) of 11.1%. This historical surge is driven by progress in coagulation biology research, a higher prevalence of thrombotic conditions, the shortcomings of conventional anticoagulants, promising early-phase clinical outcomes for FXII inhibition, and increased funding directed toward rare and specialized therapies.

The factor XII inhibitors market is projected to experience significant expansion over the coming years. By 2030, its value is anticipated to reach $2.34 billion, reflecting a compound annual growth rate (CAGR) of 10.8%. This expected growth is driven by several key factors during the forecast period, including the expansion of late-stage clinical trials, a growing demand for safer antithrombotic therapies, the rising adoption of precision medicine, increased regulatory support for novel anticoagulants, and the broadening of FXII inhibitors into inflammatory disease applications. Major developments shaping the market in the forecast period involve the increasing creation of non-bleeding anticoagulant treatments, a heightened focus on targeted modulation of coagulation pathways, more extensive clinical assessment of FXII-selective inhibitors, the expansion of RNA-based and peptide therapeutics, and the enhanced application of precision drug design techniques.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30278&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Factor XII Inhibitors Market Opportunity Drivers: What Is Creating New Revenue Potential?

The increasing occurrence of thrombotic conditions is anticipated to drive expansion in the factor XII inhibitors market. Thromboembolic disorders involve blood clots forming within veins or arteries, which can obstruct circulation and result in severe health issues. These disorders are becoming more common, driven by the growing prevalence of sedentary lifestyles that impair blood flow and elevate clot formation risks. Factor XII inhibitors address thrombotic disorders by blocking the contact activation pathway to prevent abnormal clotting while preserving normal hemostasis, thus providing effective thrombosis management with a reduced bleeding risk. For example, as reported in January 2025 by the Centers for Disease Control and Prevention (CDC), a US government agency, around 900,000 individuals in the United States experience venous thromboembolism, with an estimated 60,000–100,000 annual deaths and many more facing long-term consequences. Consequently, this rise in thrombotic disorder incidence is fueling growth in the factor XII inhibitors market.

A heightened emphasis on targeted therapies is set to stimulate growth in the factor XII inhibitors market moving forward. Targeted therapies are designed to address specific molecular abnormalities in diseases such as cancer, aiming to enhance treatment accuracy and limit damage to healthy cells. This growing focus is largely driven by progress in precision medicine, which facilitates individualized and more effective treatments aligned with unique genetic profiles. Factor XII inhibitors complement targeted therapies by specifically influencing the intrinsic coagulation pathway, making them suitable for patients susceptible to thrombotic conditions. Their precise inhibition of Factor XII lowers bleeding risks relative to standard anticoagulants, thus boosting treatment safety and efficacy. In December 2024, data from the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, revealed that the Food and Drug Administration (FDA) approved six gene therapy products in 2023, up from five in 2022. Therefore, the increasing focus on targeted therapies is driving growth in the factor XII inhibitors market.

Factor XII Inhibitors Market Segment Landscape And Growth Potential

The factor xii inhibitors market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Application: Hereditary Angioedema, Thrombosis, Inflammatory Disorders, Other Applications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors

3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies

Factor XII Inhibitors Market Innovation Trends Driving Future Development

Key players in the Factor XII Inhibitors market are concentrating on the development of cutting-edge products, including anti-FXIIa monoclonal antibodies, aimed at improving therapeutic accuracy and treatment outcomes. These antibodies are specialized biologics designed to block activated factor XII, thereby preventing abnormal blood clot formation without interfering with normal clotting processes. For example, in February 2025, CSL Behring GmbH, a biopharmaceutical firm headquartered in Germany, secured manufacturing and marketing authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This innovative human monoclonal antibody targets activated factor XII and has been approved for preventing acute episodes of hereditary angioedema (HAE). It functions by inhibiting activated factor XIIa, a critical initiator of HAE attacks, and is delivered through a user-friendly subcutaneous injection pen.

Factor XII Inhibitors Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC

Access The Complete Factor XII Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Factor XII Inhibitors Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Factor XII Inhibitors Market Over The Forecast Period?

The factor xii inhibitors market has experienced substantial growth in recent years. It is anticipated to expand from $1.4 billion in 2025 to $1.55 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.1%. This historical growth can be attributed to advancements in coagulation biology research, a rising incidence of thrombotic disorders, the limitations of traditional anticoagulants, early positive clinical results for fxii inhibition, and increasing investment in rare and specialty therapeutics.

The factor xii inhibitors market size is anticipated to undergo substantial growth in the upcoming years. It is projected to expand to $2.34 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.8%. The expansion during the forecast period is fueled by the increase in late-stage clinical trials, a rising need for safer antithrombotic therapies, growing adoption of precision medicine, enhanced regulatory support for innovative anticoagulants, and the broadened application of fxii inhibitors in inflammatory indications. Key developments expected in this period include the increased creation of non-bleeding anticoagulant treatments, a heightened emphasis on targeted coagulation pathway modulation, a growing clinical assessment of fxii selective inhibitors, the expansion of RNA-based and peptide therapeutics, and the improved implementation of precision drug design.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30278&type=smp

Which Core Factors Are Supporting The Expansion Of The Factor XII Inhibitors Market?

An anticipated increase in thrombotic disorders is projected to boost the expansion of the factor XII inhibitors market moving ahead. These conditions, where blood clots develop in veins or arteries, can obstruct blood flow and lead to severe health issues. The growing occurrence of inactive lifestyles, which leads to inadequate blood circulation and an elevated risk of clot development, is contributing to the rise in thromboembolic disorders. In managing thrombotic disorders, Factor XII inhibitors prevent pathological clot formation by interrupting the contact activation pathway, thus preserving normal blood clotting. This approach offers effective control over thrombosis while reducing the likelihood of bleeding. For instance, as reported in January 2025 by the Centers for Disease Control and Prevention (CDC), a US government agency, approximately 900,000 individuals in the United States suffer from venous thromboembolism, with an estimated 60,000-100,000 Americans dying each year, and numerous others facing lasting complications. Consequently, the escalating frequency of thrombotic disorders is stimulating the expansion of the Factor XII inhibitors market.

How Is Segment Classification Applied In The Factor XII Inhibitors Market?

The factor xii inhibitors market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Application: Hereditary Angioedema, Thrombosis, Inflammatory Disorders, Other Applications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors

3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies

What Trends Are Influencing The Factor XII Inhibitors Market Outlook?

Major companies operating in the Factor XII Inhibitors market are prioritizing the development of innovative products, such as anti-FXIIa monoclonal antibodies, to enhance therapeutic precision and improve treatment effectiveness. Anti-FXIIa monoclonal antibodies are specifically designed biologics that work by inhibiting activated factor XII, preventing abnormal clot formation while simultaneously preserving normal hemostasis. As an illustration, in February 2025, CSL Behring GmbH, a Germany-based biopharmaceutical company, secured manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This novel, human anti-activated factor XII monoclonal antibody has been approved for the prevention of acute attacks of hereditary angioedema (HAE). Its mechanism involves targeting activated factor XIIa, a key instigator in the onset of HAE attacks, and it is conveniently administered via a subcutaneous injection pen.

Who Are The Companies Shaping The Factor XII Inhibitors Market Landscape?

Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC

Access The Complete Factor XII Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report

Which Region Leads The Factor XII Inhibitors Market By Size?

North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Factor XII Inhibitors Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=30278&type=smp

Browse Through More Reports Similar to the Global Factor XII Inhibitors Market 2026, By The Business Research Company

Tumor Necrosis Factor Inhibitor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Enzyme Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Factor XII Inhibitors Market From 2026 To 2030?

The factor xii inhibitors market size has undergone rapid expansion in recent years. It is anticipated to grow from $1.4 billion in 2025 to $1.55 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.1%. The growth observed in the historic period is attributable to advancements in coagulation biology research, a rising incidence of thrombotic disorders, the inherent limitations of traditional anticoagulants, early-stage clinical success achieved with fxii inhibition, and increasing investment in rare and specialty therapeutics.

The factor xii inhibitors market size is anticipated to undergo significant expansion in the upcoming years. It is projected to reach $2.34 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.8%. This growth during the forecast period is attributable to the expansion of late-stage clinical trials, a rising demand for safer antithrombotic therapies, increased adoption of precision medicine, growing regulatory support for novel anticoagulants, and the extension of FXII inhibitors into inflammatory indications. Major trends identified for this period include the increasing development of non-bleeding anticoagulant therapies, a heightened focus on targeted coagulation pathway modulation, growing clinical evaluation of FXII selective inhibitors, the expansion of RNA-based and peptide therapeutics, and enhanced utilization of precision drug design.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30278&type=smp

Which Key Factors Are Driving The Factor XII Inhibitors Market Growth?

The increasing occurrence of thrombotic disorders is anticipated to fuel the expansion of the factor XII inhibitors market in the coming years. Thromboembolic disorders are conditions characterized by the formation of blood clots in veins or arteries, which can obstruct blood flow and lead to serious health issues. The prevalence of these disorders is growing due to an increase in sedentary lifestyles, contributing to poor blood circulation and a heightened risk of clot formation. Factor XII inhibitors aid in preventing atypical clot development in thrombotic disorders by obstructing the contact activation pathway without interfering with normal hemostasis. This approach enables effective control of thrombosis with a reduced risk of bleeding. For example, in January 2025, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that approximately 900,000 individuals in the United States are impacted by venous thromboembolism, with an estimated 60,000-100,000 Americans dying annually, and many others suffering from long-term complications. Consequently, the rising incidence of thrombotic disorders is propelling the growth of the Factor XII inhibitors market.

How Is The Factor XII Inhibitors Market Segmented Across Different Segment Categories?

The factor xii inhibitors market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Application: Hereditary Angioedema, Thrombosis, Inflammatory Disorders, Other Applications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors

3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies

Which Trends Are Guiding The Direction Of The Factor XII Inhibitors Market?

Leading companies in the Factor XII Inhibitors market are concentrating on developing innovative products, such as anti-FXIIa monoclonal antibodies, with the goal of enhancing therapeutic precision and treatment effectiveness. These anti-FXIIa monoclonal antibodies are targeted biologics that function by inhibiting activated factor XII, thereby preventing abnormal clot formation while simultaneously preserving normal hemostasis. For instance, in February 2025, CSL Behring GmbH, a biopharmaceutical company based in Germany, obtained manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This product is a novel, human anti-activated factor XII monoclonal antibody approved for the prevention of acute attacks associated with hereditary angioedema (HAE). It operates by targeting activated factor XIIa, which is a key contributor to the initiation of HAE attacks, and is administered conveniently via a subcutaneous injection pen.

Which Organizations Play A Role In The Factor XII Inhibitors Market Landscape?

Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC

Get The Full Factor XII Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report

Which Geographic Region Dominates The Factor XII Inhibitors Market?

North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Factor XII Inhibitors Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report

Browse Through More Reports Similar to the Global Factor XII Inhibitors Market 2026, By The Business Research Company

Tumor Necrosis Factor Inhibitor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Enzyme Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Factor XII Inhibitors Market From 2026 To 2030?

The factor xii inhibitors market size has undergone rapid expansion in recent years. It is anticipated to grow from $1.4 billion in 2025 to $1.55 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.1%. The growth observed in the historic period is attributable to advancements in coagulation biology research, a rising incidence of thrombotic disorders, the inherent limitations of traditional anticoagulants, early-stage clinical success achieved with fxii inhibition, and increasing investment in rare and specialty therapeutics.

The factor xii inhibitors market size is anticipated to undergo significant expansion in the upcoming years. It is projected to reach $2.34 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.8%. This growth during the forecast period is attributable to the expansion of late-stage clinical trials, a rising demand for safer antithrombotic therapies, increased adoption of precision medicine, growing regulatory support for novel anticoagulants, and the extension of FXII inhibitors into inflammatory indications. Major trends identified for this period include the increasing development of non-bleeding anticoagulant therapies, a heightened focus on targeted coagulation pathway modulation, growing clinical evaluation of FXII selective inhibitors, the expansion of RNA-based and peptide therapeutics, and enhanced utilization of precision drug design.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30278&type=smp

Which Key Factors Are Driving The Factor XII Inhibitors Market Growth?

The increasing occurrence of thrombotic disorders is anticipated to fuel the expansion of the factor XII inhibitors market in the coming years. Thromboembolic disorders are conditions characterized by the formation of blood clots in veins or arteries, which can obstruct blood flow and lead to serious health issues. The prevalence of these disorders is growing due to an increase in sedentary lifestyles, contributing to poor blood circulation and a heightened risk of clot formation. Factor XII inhibitors aid in preventing atypical clot development in thrombotic disorders by obstructing the contact activation pathway without interfering with normal hemostasis. This approach enables effective control of thrombosis with a reduced risk of bleeding. For example, in January 2025, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that approximately 900,000 individuals in the United States are impacted by venous thromboembolism, with an estimated 60,000-100,000 Americans dying annually, and many others suffering from long-term complications. Consequently, the rising incidence of thrombotic disorders is propelling the growth of the Factor XII inhibitors market.

How Is The Factor XII Inhibitors Market Segmented Across Different Segment Categories?

The factor xii inhibitors market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Application: Hereditary Angioedema, Thrombosis, Inflammatory Disorders, Other Applications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors

3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies

Which Trends Are Guiding The Direction Of The Factor XII Inhibitors Market?

Leading companies in the Factor XII Inhibitors market are concentrating on developing innovative products, such as anti-FXIIa monoclonal antibodies, with the goal of enhancing therapeutic precision and treatment effectiveness. These anti-FXIIa monoclonal antibodies are targeted biologics that function by inhibiting activated factor XII, thereby preventing abnormal clot formation while simultaneously preserving normal hemostasis. For instance, in February 2025, CSL Behring GmbH, a biopharmaceutical company based in Germany, obtained manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This product is a novel, human anti-activated factor XII monoclonal antibody approved for the prevention of acute attacks associated with hereditary angioedema (HAE). It operates by targeting activated factor XIIa, which is a key contributor to the initiation of HAE attacks, and is administered conveniently via a subcutaneous injection pen.

Which Organizations Play A Role In The Factor XII Inhibitors Market Landscape?

Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC

Get The Full Factor XII Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report

Which Geographic Region Dominates The Factor XII Inhibitors Market?

North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Factor XII Inhibitors Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report

Browse Through More Reports Similar to the Global Factor XII Inhibitors Market 2026, By The Business Research Company

Tumor Necrosis Factor Inhibitor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Enzyme Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Factor XII Inhibitors Market From 2026 To 2030?

The factor xii inhibitors market size has undergone rapid expansion in recent years. It is anticipated to grow from $1.4 billion in 2025 to $1.55 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.1%. The growth observed in the historic period is attributable to advancements in coagulation biology research, a rising incidence of thrombotic disorders, the inherent limitations of traditional anticoagulants, early-stage clinical success achieved with fxii inhibition, and increasing investment in rare and specialty therapeutics.

The factor xii inhibitors market size is anticipated to undergo significant expansion in the upcoming years. It is projected to reach $2.34 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.8%. This growth during the forecast period is attributable to the expansion of late-stage clinical trials, a rising demand for safer antithrombotic therapies, increased adoption of precision medicine, growing regulatory support for novel anticoagulants, and the extension of FXII inhibitors into inflammatory indications. Major trends identified for this period include the increasing development of non-bleeding anticoagulant therapies, a heightened focus on targeted coagulation pathway modulation, growing clinical evaluation of FXII selective inhibitors, the expansion of RNA-based and peptide therapeutics, and enhanced utilization of precision drug design.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30278&type=smp

Which Key Factors Are Driving The Factor XII Inhibitors Market Growth?

The increasing occurrence of thrombotic disorders is anticipated to fuel the expansion of the factor XII inhibitors market in the coming years. Thromboembolic disorders are conditions characterized by the formation of blood clots in veins or arteries, which can obstruct blood flow and lead to serious health issues. The prevalence of these disorders is growing due to an increase in sedentary lifestyles, contributing to poor blood circulation and a heightened risk of clot formation. Factor XII inhibitors aid in preventing atypical clot development in thrombotic disorders by obstructing the contact activation pathway without interfering with normal hemostasis. This approach enables effective control of thrombosis with a reduced risk of bleeding. For example, in January 2025, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that approximately 900,000 individuals in the United States are impacted by venous thromboembolism, with an estimated 60,000-100,000 Americans dying annually, and many others suffering from long-term complications. Consequently, the rising incidence of thrombotic disorders is propelling the growth of the Factor XII inhibitors market.

How Is The Factor XII Inhibitors Market Segmented Across Different Segment Categories?

The factor xii inhibitors market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Application: Hereditary Angioedema, Thrombosis, Inflammatory Disorders, Other Applications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors

3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies

Which Trends Are Guiding The Direction Of The Factor XII Inhibitors Market?

Leading companies in the Factor XII Inhibitors market are concentrating on developing innovative products, such as anti-FXIIa monoclonal antibodies, with the goal of enhancing therapeutic precision and treatment effectiveness. These anti-FXIIa monoclonal antibodies are targeted biologics that function by inhibiting activated factor XII, thereby preventing abnormal clot formation while simultaneously preserving normal hemostasis. For instance, in February 2025, CSL Behring GmbH, a biopharmaceutical company based in Germany, obtained manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This product is a novel, human anti-activated factor XII monoclonal antibody approved for the prevention of acute attacks associated with hereditary angioedema (HAE). It operates by targeting activated factor XIIa, which is a key contributor to the initiation of HAE attacks, and is administered conveniently via a subcutaneous injection pen.

Which Organizations Play A Role In The Factor XII Inhibitors Market Landscape?

Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC

Get The Full Factor XII Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report

Which Geographic Region Dominates The Factor XII Inhibitors Market?

North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Factor XII Inhibitors Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report

Browse Through More Reports Similar to the Global Factor XII Inhibitors Market 2026, By The Business Research Company

Tumor Necrosis Factor Inhibitor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Enzyme Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Factor XII Inhibitors Market Expected To Change Between 2026 And 2030?

The factor xii inhibitors market size has demonstrated significant expansion in recent years. It is anticipated to expand from $1.4 billion in 2025 to $1.55 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.1%. The expansion observed in the past can be ascribed to advancements in coagulation biology research, an escalating occurrence of thrombotic disorders, the constraints of conventional anticoagulants, initial positive outcomes in clinical trials for fxii inhibition, and increased investment in rare and specialized therapeutics.

The factor xii inhibitors market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $2.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.8%. This anticipated growth during the forecast period is driven by several factors, including the proliferation of late-stage clinical trials, a rising need for safer antithrombotic treatments, the growing adoption of precision medicine, increasing regulatory backing for new anticoagulants, and the extension of fxii inhibitors into inflammatory applications. Key developments expected within this period encompass the accelerated creation of non-bleeding anticoagulant therapies, a heightened emphasis on modulating targeted coagulation pathways, an increase in the clinical assessment of fxii selective inhibitors, the broadening use of rna-based and peptide therapeutics, and the improved application of precision drug design.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30278&type=smp

Which Economic Or Industry Drivers Are Impacting The Factor XII Inhibitors Market?

The increasing occurrence of thrombotic conditions is projected to drive the expansion of the factor XII inhibitors market. These conditions involve the formation of blood clots within veins or arteries, which can obstruct blood flow and lead to severe health issues. The rise in sedentary lifestyles, contributing to inadequate blood circulation and an elevated risk of clot development, is causing an increase in thromboembolic disorders. Factor XII inhibitors address thrombotic disorders by impeding irregular clot formation through the blockade of the contact activation pathway, all while preserving normal hemostasis. This mechanism ensures efficient control of thrombosis while concurrently reducing the likelihood of bleeding. For example, as reported by the US-based government agency, the Centers for Disease Control and Prevention (CDC), in January 2025, approximately 900,000 individuals in the United States suffer from venous thromboembolism, with an estimated 60,000-100,000 Americans succumbing to it each year, and many more facing enduring complications. Consequently, the growing frequency of thrombotic disorders is fueling the expansion of the Factor XII inhibitors market.

How Is The Factor XII Inhibitors Market Structured Across Different Segments?

The factor xii inhibitors market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Application: Hereditary Angioedema, Thrombosis, Inflammatory Disorders, Other Applications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors

3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies

Which Trends Are Shaping The Future Of The Factor XII Inhibitors Market?

Leading companies operating in the Factor XII Inhibitors market are concentrating on developing innovative products, such as anti-FXIIa monoclonal antibodies, with the aim of enhancing therapeutic precision and treatment effectiveness. These anti-FXIIa monoclonal antibodies are targeted biologics designed to inhibit activated factor XII, preventing abnormal clot formation while preserving normal hemostasis. For instance, in February 2025, CSL Behring GmbH, a Germany-based biopharmaceutical company, secured manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This product is a novel, human anti-activated factor XII monoclonal antibody approved for the prevention of acute attacks of hereditary angioedema (HAE). It functions by targeting activated factor XIIa, a key driver in the initiation of HAE attacks, and is administered through a convenient subcutaneous injection pen.

Which Major Players Dominate The Factor XII Inhibitors Market?

Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC

Read the full factor xii inhibitors market report here:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report

What Are The Top-Performing Regions Within The Factor XII Inhibitors Market?

North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Factor XII Inhibitors Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30278&type=smp

Browse Through More Reports Similar to the Global Factor XII Inhibitors Market 2026, By The Business Research Company

Tumor Necrosis Factor Inhibitor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Enzyme Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model